昊海生物科技(06826)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06826 昊海生物科技

已收盘 08-14 16:08:34

16.750

-0.070

-0.42%

最高16.980	最低16.610	成交量7.46万
今开16.610	昨收16.820	日振幅2.20%
总市值38.36亿	流通市值5.83亿	总股本2.29亿
成交额125.33万	换手率0.21%	流通股本3,478万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06826","market":"HK","secType":"STK","nameCN":"昊海生物科技","latestPrice":16.75,"timestamp":1786694914833,"preClose":16.82,"halted":0,"volume":74600,"delay":0,"changeRate":-0.00416171224732463,"floatShares":34780300,"shares":229000000,"eps":1.08,"marketStatus":"已收盘","change":-0.07,"latestTime":"08-14 16:08:34","open":16.61,"high":16.98,"low":16.61,"amount":1253264,"amplitude":0.021998,"askPrice":16.88,"askSize":400,"bidPrice":16.75,"bidSize":7900,"shortable":0,"etf":0,"ttmEps":1.150796,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":5,"adr":0,"listingDate":1430323200000,"exchange":"SEHK","adjPreClose":16.82,"dividendRate":0.068836,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.481912,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688366","market":"SH","secType":"STK","nameCN":"昊海生科","latestPrice":32.73,"timestamp":1786690800000,"preClose":33.02,"halted":0,"volume":1150300,"delay":0,"premium":"-56.03"}},"requestUrl":"/m/hq/s/06826","defaultTab":"news","newsList":[{"id":"1184983208","title":"昊海生物科技将于8月21日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1184983208","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184983208?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:38","pubTimestamp":1786437491,"startTime":"0","endTime":"0","summary":"上海昊海生物科技股份有限公司（06826）8月11日公告，公司董事会计划于2026年8月21日（星期五）召开会议，主要议程包括：  \n  \n1. 审议及通过集团截至2026年6月30日止六个月的中期业绩及其发布；  \n2. 讨论是否派发中期股息（如有）。  \n  \n公告显示，董事会目前由11名董事组成，其中包括4名执行董事、3名非执行董事及4名独立非执行董事。此次会议由董事会主席吴剑英召集并主持。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151163172","title":"昊海生物科技（06826）控股子公司三焦点环曲面人工晶状体获国家药监局注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=1151163172","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151163172?lang=zh_cn&edition=full","pubTime":"2026-08-06 18:30","pubTimestamp":1786012231,"startTime":"0","endTime":"0","summary":"2026年8月7日，上海昊海生物科技股份有限公司公告称，其控股子公司河南赛美视生物科技有限公司已于2026年8月4日收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》。注册证所涉产品为“三焦点环曲面人工晶状体”，证书有效期自2026年8月4日至2031年8月3日。公告显示，该产品通过国家创新医疗器械特别审批程序，成为国内首款获批上市的国产三焦点散光人工晶状体。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178427774","title":"昊海生物科技更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1178427774","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178427774?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:35","pubTimestamp":1785828939,"startTime":"0","endTime":"0","summary":"昊海生物科技于2026年8月4日披露了2026年7月的证券变动月报表。公告显示，截至7月底，公司注册股本总额为人民币228,832,195元，较上月无变化。其中，H股34,780,340股，A股194,051,855股，注册股本分别保持不变。根据公告，2026年5月29日公司曾购回234,000股H股，但截至7月底，上述购回的H股尚未完成注销。截至报告期末，公司总股本保持稳定，未有新的发行或注销行为。本次公告由公司联席公司秘书田敏于2026年8月4日签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653920985","title":"昊海生物科技于7月21日耗资约122.54万港元回购7.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653920985","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653920985?lang=zh_cn&edition=full","pubTime":"2026-07-21 23:14","pubTimestamp":1784646840,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　昊海生物科技（06826）公布，2026年7月21日耗资约122.54万港元回购7.3万股股份。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-07-21/doc-iniiqvaw8104919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06826","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182877112","title":"昊海生物科技回购7.30万股股份，涉资约122.54万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182877112","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182877112?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:26","pubTimestamp":1784625976,"startTime":"0","endTime":"0","summary":"上海昊海生物科技股份有限公司于2026年7月21日发布公告，披露当日在香港联交所场内回购H股共7.30万股，约占公司现有已发行股份总数2.25亿股的0.0324%。上述股份回购的最高价格为每股16.88港元，最低价格为每股16.64港元，合计付出约122.54万港元。公告显示，公司于2026年5月29日通过股份购回授权，可回购总数为347.80万股。上述回购股份尚未注销。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昊海生物科技回购7.30万股股份，涉资约122.54万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653275652","title":"昊海生物科技(06826)：“戴维斯双杀”近半年后，港股通资金抄底能否催化反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653275652","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653275652?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:05","pubTimestamp":1784621131,"startTime":"0","endTime":"0","summary":"今年以来，在业绩持续下滑的显性危机与公司实控人内幕交易案的“暗雷”双重夹击下，昊海生物科技迎来了一波AH股价双杀。昊海生物科技港股股价在6月29日盘中跌至15.04港元，刷新今年以来股价新低。2025年，昊海生物科技同样出现了营收、净利双降的情况。实际上，昊海生科在7月15日的大涨与近日AH两地医美板块反弹密切相关。对于昊海生物科技而言，此轮反弹行情中，港股通资金再次成为买入的主力之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06826","FLHK","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145525830","title":"昊海生物科技回购161,000股股份，耗资约263.96万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145525830","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145525830?lang=zh_cn&edition=full","pubTime":"2026-07-20 17:32","pubTimestamp":1784539922,"startTime":"0","endTime":"0","summary":"上海昊海生物科技股份有限公司于2026年7月20日公告披露，当日在香港联交所场内回购H股共161,000股，占当日已发行股份总数的约0.0716%。最高回购价为每股16.85港元，最低回购价为每股16.14港元，总耗资约263.96万港元。该部分回购股份尚未注销，暂时仍计入公司已发行股本。本次回购基于股东大会于2026年5月29日通过的购回授权，授权股份数为3,478,034股。截至公告日，公司H股已发行股份数为34,780,340股，A股已发行股份数为190,203,760股，合计普通股224,984,100股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昊海生物科技回购161,000股股份，耗资约263.96万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652915652","title":"昊海生物科技(06826)7月20日斥资约263.96万港元回购16.10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652915652","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652915652?lang=zh_cn&edition=full","pubTime":"2026-07-20 17:28","pubTimestamp":1784539736,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，于2026年7月20日该公司斥资约263.96万港元回购16.10万股，回购价格为每股16.14至16.85港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06826","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652785473","title":"【券商聚焦】中信建投：建议关注Q2医疗设备高增长公司配置机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2652785473","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652785473?lang=zh_cn&edition=full","pubTime":"2026-07-17 08:56","pubTimestamp":1784249774,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，板块26Q1业绩整体承压。医疗设备预计Q2招标偏弱，部分企业新品及海外驱动增长；医疗器械上游部分公司收入有望高增长；高值耗材受医疗合规要求提升影响，部分企业预计增长良好；IVD低基数下增速有望改善；家用器械部分企业有望延续高增长；医疗服务边际有所回暖。建议关注Q2高增长公司的配置机会，建议关注国产替代向中高端延伸，看好出海、新科技（AI、脑机接口）及并购整合等新技术落地。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986094","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01302","BK1142","00241","BK1591","BK1617","BK1584","159873","HK0000165453.HKD","02190","02235","BK1615","BK1515","BK1610","09996","BK1501","01066","BK1600","BK1189","02252","BK1583","BK1247","06826","BK1571","BK1589","LU0173614495.USD","LU0287142896.SGD","BK1222","BK1161","BK1587","BK1593","601066","BK1574","BK1100","BK1502","KCE","00853","BK1585","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123297251","title":"昊海生物科技6月股份变动月报：回购1,148,700股H股，注册股本降至2.29亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123297251","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123297251?lang=zh_cn&edition=full","pubTime":"2026-07-03 15:36","pubTimestamp":1783064170,"startTime":"0","endTime":"0","summary":"昊海生物科技于2026年7月3日发布2026年6月股份变动月报。报告期自2026年6月1日至6月30日，期间公司对H股进行了回购并注销，导致注册股本出现减少。本月末，昊海生物科技H股数量从上个月的35,929,040股减少1,148,700股至34,780,340股；A股数量维持不变，为194,051,855股；公司注册股本由人民币228,832,195元，较上月减少人民币1,148,700元，变动后的注册股本为人民币228,832,195元。此次H股回购活动于2026年6月22日实施，并经公司于2025年6月10日召开的股东大会批准，回购股份已完成注销。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186038478","title":"昊海生物科技回购114.87万股H股并完成注销，涉资约2,546.67万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186038478","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186038478?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:21","pubTimestamp":1782120084,"startTime":"0","endTime":"0","summary":"上海昊海生物科技股份有限公司于2026年6月22日发布公告，披露自2026年3月23日至5月15日期间回购合计1,148,700股H股，并于同日完成注销。该回购股份约占本次行动前公司已发行股份总数的0.508%，每股价格为港币22.17港元，总交易金额约2,546.67万港元。回购完成后，公司H股数量由35,929,040股降至34,780,340股；A股数量则保持不变，为190,203,760股，合计已发行股份总数变更为224,984,100股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昊海生物科技回购114.87万股H股并完成注销，涉资约2,546.67万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645028144","title":"昊海生物科技(06826)6月22日注销114.87万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645028144","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645028144?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:19","pubTimestamp":1782119954,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，于2026年6月22日，该公司注销114.87万股已回购股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1161","06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644732297","title":"【券商聚焦】中信建投：建议2026年加配医疗器械板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2644732297","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644732297?lang=zh_cn&edition=full","pubTime":"2026-06-18 09:24","pubTimestamp":1781745845,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券建议，2026年加配医疗器械板块，短期来看，建议把握2026年业绩改善个股的业绩和估值修复机会，多家医疗器械行业细分赛道龙头公司将于2026年迎来加速增长，同时建议关注手术机器人、脑机接口等新科技方向，相关技术突破和商业化落地有望持续催化板块热度。长期来看，医疗器械板块投资机会来自创新、出海和并购整合，板块的创新和国际化能力得到认可，估值正在重构。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984058","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","02252","BK0276","BK1615","BK1583","BK1247","BK1600","BK1610","06826","BK1617","BK1587","BK1591","BK1161","BK1222","01302","BK1189","HK0000165453.HKD","BK1571","BK1593","BK1585","BK1142","601066","BK1515","BK1502","02190","LU0173614495.USD","BK1501","LU0287142896.SGD","BK1574","BK1589","09996","01066","00241","159883","BK1584","00853","02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644931743","title":"执行董事唐敏捷增持昊海生科(06826)5000股 每股作价16.12港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644931743","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644931743?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:02","pubTimestamp":1781694143,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，6月16日，执行董事唐敏捷增持昊海生科(06826)5000股，每股作价16.12港元，总金额约为8.06万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260617/20260617190330_44960.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260617/20260617190330_44960.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK0251","BK1161","688366","EWH","BK1593","06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643093780","title":"医美概念股普跌 三生制药(01530)下挫5.67% 机构指市场逐步由流量竞争转向品牌竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2643093780","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643093780?lang=zh_cn&edition=full","pubTime":"2026-06-16 10:25","pubTimestamp":1781576726,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股普跌，截至发稿，三生制药(01530)跌5.67%，四环医药(00460)跌4.30%，巨子生物(02367)跌2.06%，复锐医疗科技(01696)跌1.98%，山东新华制药股份(00719)跌1.91%，昊海生物科技(06826)跌1.90%。消息面上，华龙证券表示，行业层面，医美市场逐步由流量竞争转向品牌竞争，精细化运营及长期用户管理成为机构提升竞争力的重要方向。产品层面，胶原蛋白注射产品商业化落地持续推进，行业发展重心正由传统填充向组织修复、皮肤质量改善及长期抗衰升级。长期来看，具备核心研发能力及品牌运营优势的企业有望持续受益于行业高质量发展趋势。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983863","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1585","02367","BK1207","SG9999004311.SGD","01696","BK1593","BK1600","BK1515","HK0000165453.HKD","BK1583","00719","LU2488822045.USD","BK1191","06826","BK1161","01530","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643205502","title":"执行董事唐敏捷增持昊海生物科技(06826)0.5万股 每股作价16.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2643205502","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643205502?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:07","pubTimestamp":1781525254,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，6月12日，执行董事唐敏捷增持昊海生物科技(06826)0.5万股，每股作价16.2港元，总金额为8.1万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260615/20260615200800_32621.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260615/20260615200800_32621.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06826","EWH","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640158880","title":"港股异动 | 昊海生科(06826)尾盘涨近3% 控股子公司三焦点人工晶状体产品获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2640158880","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640158880?lang=zh_cn&edition=full","pubTime":"2026-06-04 15:54","pubTimestamp":1780559657,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昊海生科尾盘涨近3%，截至发稿，涨2.87%，报17.87港元，成交额411.34万港元。消息面上，昊海生科公告称，其控股子公司赛美视自主研发的三焦点人工晶状体获得国家药品监督管理局的注册批准。该人工晶状体用于植入囊袋内。该产品是公司本年度获批的又一款多焦点人工晶状体产品，不仅加速并完善了公司在高端多焦点人工晶状体领域的布局，更为眼科业务的发展注入了新动能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4588","BK4585","BK1100","BK0251","VXUS","BK1583","688366","09996","06826","BK1161","BK1593","159883","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106435190","title":"昊海生物科技发布5月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1106435190","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106435190?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:40","pubTimestamp":1780386053,"startTime":"0","endTime":"0","summary":"上海昊海生物科技股份有限公司于2026年6月2日发布截至2026年5月31日的股份变动月报。公告显示，公司本月注册股本未发生变动，合计仍为人民币229,980,895元。根据报告，截至5月末，公司已发行H股为35,929,040股，A股为194,051,855股，合计较上月无增减变化。与此同时，公司此前于2025年6月10日购回的1,148,700股H股截至2026年5月31日仍未注销。报告显示，上述股份变动及购回安排均已获得公司董事会正式授权，并遵守香港联交所《上市规则》及相关法律法规的规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639667526","title":"昊海生物科技：执行董事侯永泰辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2639667526","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639667526?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:31","pubTimestamp":1780065060,"startTime":"0","endTime":"0","summary":"南财智讯5月29日电，昊海生物科技（06826.HK）公告，因年龄原因，侯永泰已提呈辞任公司执行董事、董事会主席及相关委员会成员职务，自2026年5月29日起生效。辞任后，侯永泰不再担任公司法定代表人，但将继续留任部分附属公司职务并获任首席科学顾问。同时，董事会宣布由执行董事兼总经理吴剑英接任董事会主席及法定代表人职务。此外，董事会各专门委员会组成亦相应调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605293754742295.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754742295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06826","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161712817","title":"昊海生物科技更新末期股息派发方案 每股0.688247港元 7月10日派付","url":"https://stock-news.laohu8.com/highlight/detail?id=1161712817","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161712817?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:25","pubTimestamp":1780064757,"startTime":"0","endTime":"0","summary":"昊海生物科技发布末期股息更新公告，披露了派息金额、汇率及派发日期。公司宣派截至2025年12月31日止年度末期股息每股0.6元人民币，按汇率1.147078折算，预设派发货币为每股0.688247港元。此次股息派发的除净日为2026年6月4日，递交股份过户文件以符合获取股息分派的最后时限为2026年6月5日16:30，暂停办理股份过户登记手续的日期为2026年6月8日至6月11日，记录日期为6月11日，股息正式派发日为2026年7月10日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"昊海生物科技更新末期股息派发方案 每股0.688247港元 7月10日派付","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3healthcare.com/","stockEarnings":[{"period":"1week","weight":0.0319},{"period":"1month","weight":0.0396},{"period":"3month","weight":-0.1897},{"period":"6month","weight":-0.3456},{"period":"1year","weight":-0.3961},{"period":"ytd","weight":-0.2833}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0441},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海昊海生物科技股份有限公司是一家主要从事生产及销售生物制品、医用透明质酸及人工晶状体、研发生物工程及药品及提供相关服务的中国公司。眼科业务已覆盖白内障治疗、近视防控与屈光矫正及眼表用药、提供人工晶状体及角膜塑形镜等产品的视光材料。医疗美容与创面护理产品覆盖玻尿酸真皮填充剂、皮肤和黏膜浅层组织补充用透明质酸凝胶等。骨科产品包含骨科关节腔黏弹补充剂等。防黏连及止血产品包括医用几丁糖（防黏连用）、医用透明质酸钠凝胶和胶原蛋白海绵。该公司主要在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.002084},{"month":2,"riseRate":0.363636,"avgChangeRate":0.018835},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.01456},{"month":4,"riseRate":0.818182,"avgChangeRate":0.062957},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.02212},{"month":6,"riseRate":0.25,"avgChangeRate":-0.018497},{"month":7,"riseRate":0.583333,"avgChangeRate":0.058203},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.019691},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.016756},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.029248},{"month":11,"riseRate":0.545455,"avgChangeRate":-0.00961},{"month":12,"riseRate":0.545455,"avgChangeRate":0.022656}],"exchange":"SEHK","name":"昊海生物科技","nameEN":"HAOHAI BIOTEC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昊海生物科技(06826)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昊海生物科技(06826)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昊海生物科技,06826,昊海生物科技股票,昊海生物科技股票老虎,昊海生物科技股票老虎国际,昊海生物科技行情,昊海生物科技股票行情,昊海生物科技股价,昊海生物科技股市,昊海生物科技股票价格,昊海生物科技股票交易,昊海生物科技股票购买,昊海生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昊海生物科技(06826)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昊海生物科技(06826)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}